Previous studies have incorporated epitopes from a single antigen to stimulate anti-tumour responses (3) but few have used epitope combinations that could widen the applicability of vaccines to stimulate both CD4+ and CD8+ T cell responses and recognise multiple tumour cell populations (2). The gene discussed is CD4; the disease is neoplasm.